Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.